VIENNA, Va., May 16, 2024--CEL-SCI Corporation reports second quarter fiscal 2024 financial results.
VIENNA, Va., May 08, 2024--CEL-SCI receives FDA go-ahead for its confirmatory study of Multikine in the treatment of head & neck cancer.
VIENNA, Va., April 23, 2024--CEL-SCI appoints Mario Gobbo to its Board of Directors.